JP6877419B2 - 治療の方法およびそのために有用な剤 - Google Patents

治療の方法およびそのために有用な剤 Download PDF

Info

Publication number
JP6877419B2
JP6877419B2 JP2018521887A JP2018521887A JP6877419B2 JP 6877419 B2 JP6877419 B2 JP 6877419B2 JP 2018521887 A JP2018521887 A JP 2018521887A JP 2018521887 A JP2018521887 A JP 2018521887A JP 6877419 B2 JP6877419 B2 JP 6877419B2
Authority
JP
Japan
Prior art keywords
epha4
amino acid
disease
condition
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018521887A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019501112A (ja
JP2019501112A5 (enExample
Inventor
ペリー バートレット
ペリー バートレット
アンドリュー ボイド
アンドリュー ボイド
マイク ジェロメッタ
マイク ジェロメッタ
リアン クーパー
リアン クーパー
Original Assignee
ザ ユニバーシティー オブ クイーンズランド
ザ ユニバーシティー オブ クイーンズランド
ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ
ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015904387A external-priority patent/AU2015904387A0/en
Application filed by ザ ユニバーシティー オブ クイーンズランド, ザ ユニバーシティー オブ クイーンズランド, ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ, ザ カウンシル オブ ザ クイーンズランド インスティテュート オブ メディカル リサーチ filed Critical ザ ユニバーシティー オブ クイーンズランド
Publication of JP2019501112A publication Critical patent/JP2019501112A/ja
Publication of JP2019501112A5 publication Critical patent/JP2019501112A5/ja
Application granted granted Critical
Publication of JP6877419B2 publication Critical patent/JP6877419B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2018521887A 2015-10-27 2016-10-27 治療の方法およびそのために有用な剤 Active JP6877419B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2015904387A AU2015904387A0 (en) 2015-10-27 A method of treatment and agents useful for same
AU2015904387 2015-10-27
PCT/AU2016/051010 WO2017070738A1 (en) 2015-10-27 2016-10-27 A method of treatment and agents useful for same

Publications (3)

Publication Number Publication Date
JP2019501112A JP2019501112A (ja) 2019-01-17
JP2019501112A5 JP2019501112A5 (enExample) 2019-12-05
JP6877419B2 true JP6877419B2 (ja) 2021-05-26

Family

ID=58629613

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018521887A Active JP6877419B2 (ja) 2015-10-27 2016-10-27 治療の方法およびそのために有用な剤

Country Status (7)

Country Link
US (1) US10617738B2 (enExample)
EP (1) EP3368551B1 (enExample)
JP (1) JP6877419B2 (enExample)
CN (1) CN108884135B (enExample)
AU (1) AU2016345063B2 (enExample)
ES (1) ES2959601T3 (enExample)
WO (1) WO2017070738A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110702916B (zh) * 2019-04-15 2022-06-21 四川大学华西医院 一种整合蛋白质组和糖蛋白组的定量分析方法
EP4308149A4 (en) * 2021-03-18 2025-02-26 Valery Krasnoperov Use of sephb4-hsa fusion protein as a first-line therapy in cancer treatment
AU2022388189A1 (en) * 2021-11-11 2024-05-02 Eisai R&D Management Co., Ltd. Anti-epha4 antibody
WO2023154948A1 (en) * 2022-02-14 2023-08-17 Vasgene Therapeutics Inc. Ephrin type-b receptor 4 (ephb4) agents and production thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
EP0425731B1 (de) 1989-11-03 1994-01-19 Siemens Aktiengesellschaft Controller-Bussystem für einen programmierbaren, flexiblen Digitalsignal-Multiplexer
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
DE69423522T2 (de) 1993-04-27 2000-09-21 Cytotherapeutics, Inc. Membran aus einem acrylnitrilpolymer
NZ269041A (en) 1993-06-23 1998-02-26 Univ Brown Res Found Implantable encapsulation device having a cell-tight dry seal at an opening thereof
SG48813A1 (en) 1993-08-12 1998-05-18 Cytotherapeutics Inc Improved composition and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5550050A (en) 1994-04-15 1996-08-27 Cytotherapeutics, Inc. Method for implanting encapsulated cells in a host
US5853717A (en) 1994-07-20 1998-12-29 Cytotherapeutics, Inc. Methods and compositions of growth control for cells encapsulated within bioartificial organs
US5834029A (en) 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
CA2202747A1 (en) 1995-06-01 1996-12-05 Dennis Keen Warren Communication system to provide called party location and pre-call warning
IN181898B (enExample) 1995-06-07 1998-10-24 Cytotherapeutics Inc
WO1997012635A1 (en) 1995-10-02 1997-04-10 Cytotherapeutics, Inc. Method for treating amyotrophic lateral sclerosis
AUPP674898A0 (en) * 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
JP2007525203A (ja) * 2004-02-27 2007-09-06 オンコセラピー・サイエンス株式会社 ＰＲＣおよびＰＤＡＣａの治療標的としてのＥｐｈＡ４
US20080003210A1 (en) 2006-03-13 2008-01-03 Medimmune, Inc. Non-human primate receptor tyrosine kinases
WO2008150010A1 (ja) * 2007-06-08 2008-12-11 Eisai R & D Management Co., Ltd. γ-セクレターゼの新規基質EphA4を利用したスクリーニング方法
EP2223999B1 (en) * 2007-11-30 2017-10-18 Eisai R&D Management Co., Ltd. Epha4 polypeptide having novel activity and use thereof
EP2260864A1 (en) * 2009-06-10 2010-12-15 University of Melbourne Therapeutic applications
EP2653552B1 (en) * 2010-12-17 2016-10-19 Eisai R&D Management Co., Ltd. SCREENING METHOD USING GELATINASE-MEDIATED EphA4 CLEAVAGE REACTION AS AN INDICATOR
MY199344A (en) 2013-02-18 2023-10-24 Vegenics Pty Ltd Ligand binding molecules and uses thereof

Also Published As

Publication number Publication date
US20180339020A1 (en) 2018-11-29
AU2016345063A2 (en) 2018-07-19
WO2017070738A1 (en) 2017-05-04
EP3368551A1 (en) 2018-09-05
EP3368551B1 (en) 2023-07-12
ES2959601T3 (es) 2024-02-27
US10617738B2 (en) 2020-04-14
CN108884135B (zh) 2024-03-26
CA3003294A1 (en) 2017-05-04
CN108884135A (zh) 2018-11-23
AU2016345063B2 (en) 2021-08-05
JP2019501112A (ja) 2019-01-17
AU2016345063A1 (en) 2018-05-17
EP3368551A4 (en) 2019-06-05

Similar Documents

Publication Publication Date Title
EP3561058A1 (en) Fusion protein including bdnf
CN107074928A (zh) 新型猫促红细胞生成素受体激动剂
WO2022089605A1 (en) Modified red blood cells and uses thereof for delivering agents
CN108884135B (zh) 治疗方法以及可用于其中的药剂
US20260035706A1 (en) Fusion polypeptides
WO2018205622A1 (zh) 具有抑制肿瘤功能的peg化多肽及其制备方法与应用
CA3003294C (en) Modified epha4 and uses thereof
AU2022325383B2 (en) GPC3-TARGETED ANTIBODY INTERFERON α FUSION PROTEIN AND USE THEREOF
KR102917499B1 (ko) 백혈병 억제 인자 활성을 억제하기 위한 가용성 폴리펩타이드 및 이의 사용 방법
KR102485892B1 (ko) 고양이 과립구 집락 자극인자 및 혈청 알부민에 대한 항원 결합 단편을 포함하는 융합 단백질 및 이의 용도
CN116139278B (zh) 一种tim-3棕榈酰化修饰及靶向多肽在肿瘤免疫治疗中的应用
US20250250320A1 (en) Thrombopoietin receptor fragments and uses thereof
EP2207799A2 (en) Use of n-terminal and c-terminal proteomics technology to enhance protein therapeutics and diagnostics
CN120500541A (zh) 制备融合多肽的方法
KR20260067446A (ko) 암 조직 내 형질 세포 유래 신규 항체 또는 이의 항원 결합 단편, 및 이의 용도
CN117642422A (zh) 用于降低抗体-脂肪酶结合的结构
WO2024123702A1 (en) Soluble angiotensin-converting enzyme 2 (ace2) proteins and ace2 fusion proteins
HK40108872A (zh) 用於降低抗体-脂肪酶结合的结构
Fellermeier Bifunctional immunostimulatory fusion proteins for therapeutic applications
AU2013227987A1 (en) Anti-hepcidin antibodies and methods of use
Bernardini et al. Erythropoietin receptor modulates breast cancer cell response to tamoxifen treatment
HK40008823A (en) Fusion protein including bdnf
HK1165461A (en) In tumours differentially expressed gene products and use of the same
HK1165478A (en) In tumours differentially expressed gene products and use of the same
HK1165471A (en) In tumours differentially expressed gene products and use of the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20191025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210427

R150 Certificate of patent or registration of utility model

Ref document number: 6877419

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE

Ref document number: 6877419

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250